As safinamide inhibits the degradation of dopamine by inhibiting MAO-B (Kurihara et al. 2021) and an excess of dopamine causes dyskinesia, it is considered that a slight increase in ON-TD during the initial treatment phase is caused by the dopaminergic action of safinamide. This evidence concerns the gene MAOB and drug-induced dyskinesia.